Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT05548270 is registered in ClinicalTrials.gov with Repurposed Therapeutics, Inc. as lead sponsor.

NCT NCT05548270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05548270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Lead sponsor
Repurposed Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 23, 2022
Completion date
November 29, 2022
Enrollment
503 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

motion sickness